Get started
Author

Hanyi Ding

Observed name: Han-Yi Ding
ORCID: 0000-0002-7295-8360
Observed ORCID: 0000-0002-7295-8360
OpenAlex ID: A5078772381
CAR‐T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status
2022 · Juan Du, Runhong Wei, et al. · American Journal of Hematology · 32
Implications of RNA pseudouridylation for cancer biology and therapeutics: a narrative review
2024 · Hanyi Ding, Na Liu, et al. · Journal of Translational Medicine · 26
PDF
A bibliometric analysis of CD38-targeting antibody therapy in multiple myeloma from 1985 to 2021
2022 · Hanyi Ding, Xiaoyuan Zhang, et al. · Translational Cancer Research · 8
PDF
Functions of N6-methyladenosine (m6A) RNA modifications in acute myeloid leukemia
2024 · Zehao Fang, Hanyi Ding, et al. · Journal of Leukocyte Biology · 7
The Survival Implications of Extramedullary Disease in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
2023 · Ping Liu, Jie Sun, et al. · 1
PDF
Efficacy of Surgery in Patients with Stage I Primary Parotid Gland Lymphoma: A Population-Based Study
2022 · Xiaoyu He, Dongxu Gang, et al. · Journal of Oncology · 1
PDF
[Toxicity Management and Efficacy Evaluation of BCMA-CART in the Treatment of Relapsed and Refractory Multiple Myeloma].
2022 · Xiao-Yuan Zhang, Han-Yi Ding, et al. · PubMed · 1
Works count: 7
Citation count: 76
H-index: 4
I10-index: 2
Year
Topic
Type